Fecal Microbiota Transplantation Using RBX2660 for the Prevention of Recurrent Urinary Tract Infections Due to Multidrug Resistant Organisms
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 02 Jan 2018
At a glance
- Drugs RBX 2660 (Primary)
- Indications Urinary tract infections
- Focus Adverse reactions
- 26 Dec 2017 Planned initiation date changed from 15 Dec 2017 to 2 Dec 2017.
- 13 Jan 2016 New trial record
- 11 Jan 2016 According to a Rebiotix media release, first patient has been treated in this trial.